Welcome Back
Join CoinTime
Sign in with email
Sign up with email
Check your inbox
AVEO Oncology
About
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
- 101 - 250
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $35M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2001
- Number Of Employee
- 101 - 250
- Operating Status
- Active
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec.The company was established in 2001 and is based in Cambridge, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 10, 2020 | Post-IPO Debt | $35M | 1 |
Hercules Capital
|
— | Detail |
| May 28, 2010 | Post-IPO Equity | $25M | 1 |
Hercules Capital
|
— | Detail |
| May 5, 2005 | Series C | $5M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
|
|
— | Series C |
